BTX BioTime | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
BTX BioTime

An SI Board Since July 2014

Posts	SubjectMarks	Bans	Symbol
69	5	0	BTX

Emcee: Savant	Type: Moderated

Introduction Market Data Compact

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime's focus is on pluripotent stem cell technology based on human embryonic stem ("hES") cells and induced pluripotent stem ("iPS") cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime's therapeutic and research products include a wide array of proprietary PureStem(R) progenitors, HyStem(R) hydrogels, culture media, and differentiation kits. BioTime is developing Renevia(TM) (a HyStem(R) product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia(TM), in 2014. In addition, BioTime has developed Hextend(R) , a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend(R) is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
69	BioTime Conducts Sale of Shares in OncoCyte Corporation 4:15 PM ET 7/2/19 \| Bus	Savant	-	7/29/2019
68	RT AST> sterias Biotherapeutics to Discuss Cancer Immunotherapy Product	Savant	-	5/17/2018
67	RT--Asterias/they might want to do a study of salamander radial glial stem cells	Savant	-	11/2/2017
66	Asterias Announces Two Significant Developments for Spinal Cord Injury Prog	Savant	-	10/2/2017
65	Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VA	Savant	-	9/26/2017
64	Asterias' AST-OPC1 Clinical Trial Will Continue as Planned Following Re	Savant	-	9/25/2017
63	ALAMEDA, Calif.--(BUSINESS WIRE)--September 14, 2017-- BioTime, Inc. (NYSE Amer	Savant	-	9/14/2017
62	BioTime Inc. (BTX) filed a Form 8K - Changes to Articles of Incorporation or Byl	Savant	-	9/14/2017
61	FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, In	Savant	-	9/6/2017
60	Asterias Biotherapeutics Reports Second Quarter Financial Results and Reviews Re	Savant	-	8/16/2017
59	AST Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial	Savant	-	8/9/2017
58	AST Former Quadriplegic Enrolled in Asterias' SCiStar Study to Throw Ceremo	Savant	-	8/8/2017
57	Asterias Biotherapeutics Opens Two Additional Clinical Sites for AST-OPC1 SCiSta	Savant	-	8/3/2017
56	AST ... Ability to enroll patients with second most common cervical spinal cord	Savant	-	7/10/2017
55	Presentation by AST today 9 mon. results slides @ link Third patient recovers t	Savant	-	6/13/2017
54	Further great news for spinal injury patients.. Update on Full Six-Patient Coh	Savant	-	3/21/2017
53	BTX & OCX BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Su	Savant	-	2/22/2017
52	BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company de	Savant	-	2/15/2017
51	BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for	Savant	-	2/6/2017
50	AST - AST.WS Asterias Biotherapeutics Extends the Expiration Date of Certain W	Savant	-	2/3/2017
49	BioTime to Present at Noble Capital Markets Thirteenth Annual Investor Conferenc	Savant	-	1/26/2017
48	Additional Data From BioTimes OpRegen(R) Clinical Trial in Dry-AMD to be Present	Savant	-	1/19/2017
47	Asterias Announces Successful Commencement of Operations at New GMP Manufacturin	Savant	-	1/9/2017
46	BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therap	Savant	-	1/3/2017
45	Ascendance Biotechnology Licenses the Right to Manufacture, Market and Sell Cyti	Savant	-	12/28/2016

Go to reply# or date (mm/dd/yy):